stem-cell-congress-cardiology-2018-posters

Biomedical Research

Volume 29

Page 53

Note:

allied

academies

CARDIOLOGY AND CARDIOVASCULAR MEDICINE

STEM CELLS AND REGENERATIVE MEDICINE

International Conference on

J u n e 1 8 - 1 9 , 2 0 1 8 | O s a k a , J a p a n

Joint Event on

STENTS WITH GROWTH FACTOR SECRETING MSCS ENHANCED

RE-ENDOTHELIALIZATION AND DECREASED RESTENOSIS IN

SWINE MODEL

Hyun-Kyung

Seoul National University, South Korea

urrently, cardiac stenting is the most effective and least invasive approach to treating the disease. However, in-stent

restenosis is a complex chronic side-effect of the stenting treatment. In this study, to reduce stent restenosis and induce re-

endothelialization within the artery, we applied coronary stents coated with stem cells secreting angiogenic growth factors via an

inducible genome-editing system. After confirming the characteristics of the cells and their adhesion properties on the stents, we

transplanted the stents into a swine model to evaluate the restenosis and potential therapeutic use of the stents with stem cells.

Restenosis was evaluated via optical coherence tomography (OCT), micro-computed tomography (mCT) and angiography, and re-

endothelialization by immunostaining after cardiac stent treatment. Compared to a bare metal stent (BMS) or a parental umbilical

cord blood-derived mesenchymal stem cells (UCB-MSC)-coated stent, the stents that had stem cells capable of the controlled

release of hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) successfully reduced re-stenosis within

the stent and induced natural re-endothelialization. Furthermore, UCB-MSCs exhibited the ability to differentiate into endothelial

cells in Matrigel, and HGF and VEGF improved the differentiation. Our study indicates that the stents coated with UCB-MSCs

secreting VEGF/HGF reduced the restenosis side effects of cardiac stenting with improved re-endothelialization.

Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C2-006